El-Kady, M., El-Sahhar, M., El-Azab, T., Ali, A. (2021). Effect of DAAs on improvement of liver fibrosis assessed by transiet elastography and associated risk factors for accelerating liver fibrosis. Benha Medical Journal, 38(3), 972-983. doi: 10.21608/bmfj.2021.88790.1450
Mostafa El-Kady; Medhat El-Sahhar; Tamer El-Azab; Abdel rahman Ali. "Effect of DAAs on improvement of liver fibrosis assessed by transiet elastography and associated risk factors for accelerating liver fibrosis". Benha Medical Journal, 38, 3, 2021, 972-983. doi: 10.21608/bmfj.2021.88790.1450
El-Kady, M., El-Sahhar, M., El-Azab, T., Ali, A. (2021). 'Effect of DAAs on improvement of liver fibrosis assessed by transiet elastography and associated risk factors for accelerating liver fibrosis', Benha Medical Journal, 38(3), pp. 972-983. doi: 10.21608/bmfj.2021.88790.1450
El-Kady, M., El-Sahhar, M., El-Azab, T., Ali, A. Effect of DAAs on improvement of liver fibrosis assessed by transiet elastography and associated risk factors for accelerating liver fibrosis. Benha Medical Journal, 2021; 38(3): 972-983. doi: 10.21608/bmfj.2021.88790.1450
Effect of DAAs on improvement of liver fibrosis assessed by transiet elastography and associated risk factors for accelerating liver fibrosis
1Dean of Faculty of medicine Benha University & former Head of Hepatology, Gastroenterology and Infectious Diseases, Faculty of medicine, Benha University
2Consultant of Hepatology and Gastroenterology at Police Hospitals
3Lecturer of Hepatology,Gastroenterology and Infectious Diseases. Faculty of medicine - Benha University
4MBBCH
Abstract
Background: Egypt started a national treatment program intending to provide cure for Egyptian HCV-infected patients. Yet, with the development of highly-effective direct acting antivirals (DAAs) for HCV, elimination of viral hepatitis has become a real possibility. This study aimed to to evaluate the impact of DAAs on achievement of improvement in liver fibrosis, and to evaluate risk factors associated with progression of liver fibrosis in patients achieved sustained virological response (SVR). Method: the study included 300 patients diagnosed with chronic HCV infection started their treatment protocol form 2016 who were divided into two groups; Group I included patients who received Sofosbuvir + Simeprevir ± Ribavirin as dual or triple therapy (for 12 weeks) for HCV treatment, and Group II included patients who received Sofosbuvir + Daclatasvir ± Ribavirin as dual or triple therapy (for 12 weeks) for HCV treatment. All cases were subjected to complete history taking, thorough physical examination, routine laboratory investigations, pelviabdominal US together with transient elastography were ordered for all cases. Results and conclusion: both HCV treatment regimens showed improvement in liver fibrosis, fibro scan parameters showed a significant decrease in both groups compared to the baseline. There was a significant negative correlation between fibro scan parameter decrease with age, BMI, and HbA1C levels. There was no difference in degree of improvement of liver fibrosis between both regimens.
View on SCiNiTO
Top